A Randomized Controlled Trial Comparing Two Doses of Caffeine for Apnoea in Prematurity

Area of Science:

• Neonatal Medicine
• Pharmacology
• Pediatric Critical Care

Background:

• Caffeine is a common treatment for preventing apnoea in premature infants.
• The optimal dosage of caffeine for this purpose has been unclear.
• Methylxanthine therapy is standard in neonatal intensive care units.

Purpose of the Study:

• To compare the efficacy of two different caffeine dosages for preventing apnoea in preterm infants.
• To determine if a higher caffeine dose regimen is more effective than a standard dose.
• To assess the impact of caffeine dosage on apnoea frequency and duration.

Main Methods:

• A randomized clinical trial involving 78 preterm infants (≤32 weeks gestation).
• Infants were assigned to either a higher dose (40 mg/kg/day loading, 20 mg/kg/day maintenance) or standard dose (20 mg/kg/day loading, 10 mg/kg/day maintenance) of caffeine.
• Primary outcomes included apnoea frequency and total days of apnoea.

Main Results:

• No statistically significant difference in apnoea frequency between the higher dose and standard dose groups (p=0.839).
• Similar total days of apnoea were observed in both treatment groups (p=0.928).
• Adverse events did not differ significantly between the two caffeine dosage regimens.

Conclusions:

• The study does not support the use of higher caffeine doses for the prevention of apnoea in prematurity.
• Standard caffeine dosing appears sufficient and does not increase adverse events compared to higher doses.
• Further research may be needed to establish definitive optimal dosing strategies for caffeine in preterm infants.